A Theranos redux & and vaccine outreach via EHRs

‘Move fast and break things’ meets medicine

When the trial of Elizabeth Holmes finally begins next week, it will once again put the Theranos saga in the spotlight. No matter its outcome, Casey reports, there may be fallout for the biotech and digital health sectors, which have raised significant sums in the past year — in some cases, without as much evidence in hand as one might expect. Holmes “was allegedly able to exploit some of the exuberance of the Silicon Valley types for a health care product,” said Harvard’s Glenn Cohen.